| Luminari, Stefano |
OLYMPIA-2, NCT06097364: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma |
|
|
| Recruiting | 3 | 733 | Europe, US, RoW | Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prenisolone, Deltasone/Omnipred | Regeneron Pharmaceuticals | Follicular Lymphoma (FL) | 07/29 | 07/29 | | |
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi |
|
|
| Recruiting | 3 | 190 | Europe | Radiotherapy, Radiotherapy plus Obinutuzumab | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Follicular Lymphoma | 04/31 | 04/31 | | |
NCT04417166: Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma |
|
|
| Recruiting | 2 | 30 | RoW | Pembrolizumab, Keytruda, Involved Field Radiation Therapy | International Extranodal Lymphoma Study Group (IELSG), Merck Sharp & Dohme LLC | Lymphoma, Extranodal NK-T-Cell | 12/26 | 12/26 | | |
| Recruiting | 1/2 | 122 | Europe | Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Relapsed or Refractory Hodgkin's Lymphoma | 04/27 | 04/30 | | |
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice |
|
|
| Recruiting | N/A | 1500 | Europe | "novel" MAB (alone or in combination) | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Non-Hodgkin Lymphoma, B-cell | 10/38 | 10/38 | | |
